Physician profile
Loren Shkolnik
NPI 1548746779
$6,587.07
in general payments reported to CMS, 2019-2025
14 companies · $3,229 in 2025
The $3,229 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $696 · 2023: $955 · 2024: $1,333 · 2025: $3,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Consulting Fee: $2,369 · Education: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.82 |
| Consulting Fee | $2,369.00 |
| Education | $534.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,272.70 | 2023-2025 | Sotyktu |
| Ucb, INC. | $918.76 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $724.38 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $688.58 | 2022-2025 | Absorica Ld, Winlevi |
| Journey Medical Corporation | $511.31 | 2022-2025 | |
| Almirall LLC | $379.67 | 2021-2023 | Klisyri |
| Dermavant Sciences, INC. | $295.54 | 2024 | Vtama |
| Lilly USA, LLC | $197.37 | 2023-2025 | Olumiant, Taltz, Zepbound |
| Sanofi-Aventis U.S. LLC | $184.99 | 2022-2024 | |
| Galderma Laboratories, L.P. | $109.63 | 2023-2025 | Epiduo, Twyneo |
| Arcutis Biotherapeutics, INC. | $105.43 | 2024 | Zoryve |
| Genzyme Corporation | $101.19 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.84 | 2024 | Siliq |
| Leo Pharma INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Shkolnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.